FEB 13, 2020 5:04 AM PST

Protein that suppresses immune system linked to lupus

WRITTEN BY: Tara Fernandez

 

A study published in Human Immunology has described, for the first time, a link between an immunosuppressive protein on the surface of T cells and the development of systemic lupus erythematosus, or SLE. This protein, human leukocyte antigen G (HLA-G), is expressed on fetal derived placental cells and is thought to play a role in immune tolerance during pregnancy.

HLA-G has been the subject of intense study in the last two decades. In particular, scientists have been interested in how HLA-G-mediated pathways affect rejection after organ transplantation, or how tumors suppress hijack these to evade immune detection. 

Now, the research team led by Francesco Puppo at the University of Genoa has identified that patients with SLE have significantly elevated levels of HLA-G. The protein was found on the membrane of peripheral blood mononuclear cells, a subset of white blood cells that includes T cells and monocytes. The significant difference in HLA-G levels between lupus patients and healthy controls points to the protein’s possible involvement in the onset or progression of this autoimmune disease.

SLE affects nearly every organ system from the skin, joints and central nervous system to the brain and kidneys. The disease is more prevalent in women than men and is thought to be a result of complex genetic, environmental and hormonal factors. Lupus is characterized by an exaggerated immune response to the body’s own cells and tissues, causing this widespread organ damage.

 

 

Based on their findings, the authors hypothesize that the increased production of HLA-G on the surface of immune cells could reflect an attempt to control the imbalanced immune responses occurring during the systemic autoimmune diseases.

Further clinical studies are due to establish whether HLA-G could be leveraged for diagnostic or therapeutic purposes.

 

Sources: Scleroderma News, Human Immunology.

 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 14, 2020
Immunology
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
MAY 14, 2020
Antibody-laden Nanoparticles to Help COVID Patients Breathe Easy
Antibodies are a powerful countermeasure against COVID-19. Not only can they relieve symptoms in patients experiencing s ...
MAY 17, 2020
Genetics & Genomics
How Non-Coding Genomic Regions Influence Autoimmune Disease
MAY 17, 2020
How Non-Coding Genomic Regions Influence Autoimmune Disease
Scientists have gained new insight into autoimmune and allergic disorders.
JUN 14, 2020
Microbiology
Amping Up Immunity to Respiratory Viruses by Targeting Memory T Cells in the Lungs
JUN 14, 2020
Amping Up Immunity to Respiratory Viruses by Targeting Memory T Cells in the Lungs
It's easier than thought to activate immune cells that reside in the lungs and are involved in long-term immunity. Image ...
JUN 23, 2020
Immunology
Nanosponges Mop up Viruses to Treat COVID Infections
JUN 23, 2020
Nanosponges Mop up Viruses to Treat COVID Infections
  Scientists have developed an experimental therapy for COVID-19 that uses coated nanoparticles to intercept SARS-C ...
JUL 07, 2020
Immunology
A Step Towards a Cure for Rare Polio-Like Disease in Children
JUL 07, 2020
A Step Towards a Cure for Rare Polio-Like Disease in Children
Acute flaccid myelitis, or AFM, is a rare but devastatingly debilitating neurologic disease in children caused by a resp ...
JUL 13, 2020
Drug Discovery & Development
Russia Completes First Human Trial for COVID-19 Vaccine
JUL 13, 2020
Russia Completes First Human Trial for COVID-19 Vaccine
The Sechenov University Center for Clinical Research in Moscow, Russia, has completed its first round of clinical trials ...
Loading Comments...